Quick Answer
Caris Life Sciences, Inc. reported Diluted EPS of $3.22 per share (loss) for fiscal year 2025.
Caris Life Sciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.22 | +69.8% |
| 2024 | -$10.66 | +19.5% |
| 2023 | -$13.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.08 | +103.1% | +101.0% |
| June 30, 2025 | -$7.97 | -213.8% | -207.7% |
| September 30, 2024 | -$2.59 | — | -2.0% |
| June 30, 2024 | -$2.54 | — | — |
- Caris Life Sciences, Inc. showed an increase of +69.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Caris Life Sciences, Inc.’s diluted eps has grown by 75.7% (from $13.24 per share (loss) to $3.22 per share (loss)).
- The most recent figure is from Caris Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: